| Selected Quarterly Financial Data (Unaudited) |
Quarterly financial information for fiscal 2016 and 2015 are presented
in the following table, in thousands, except per share data:
| |
|
For the Quarter Ending |
| |
|
March 31 |
|
June 30 |
|
September 30 |
|
December 31 |
| 2016: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lymphoseek sales revenue |
|
$ |
3,783 |
|
|
$ |
4,232 |
|
|
$ |
6,690 |
|
|
$ |
2,332 |
|
| Lymphoseek license revenue |
|
|
254 |
|
|
|
246 |
|
|
|
1,296 |
|
|
|
— |
|
| Grant and other revenue |
|
|
686 |
|
|
|
917 |
|
|
|
511 |
|
|
|
1,023 |
|
| Gross profit |
|
|
4,188 |
|
|
|
4,834 |
|
|
|
7,575 |
|
|
|
3,076 |
|
| Operating expenses |
|
|
6,756 |
|
|
|
5,414 |
|
|
|
4,217 |
|
|
|
5,509 |
|
| Operating income (loss) |
|
|
(2,568 |
) |
|
|
(580 |
) |
|
|
3,358 |
|
|
|
(2,433 |
) |
| Net loss attributable to common stockholders |
|
|
(3,686 |
) |
|
|
(6,681 |
) |
|
|
(59 |
) |
|
|
(3,883 |
) |
| Basic and diluted net loss per share (1) |
|
$ |
(0.02 |
) |
|
$ |
(0.04 |
) |
|
$ |
(0.00 |
) |
|
$ |
(0.03 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lymphoseek sales revenue |
|
$ |
1,835 |
|
|
$ |
1,964 |
|
|
$ |
2,953 |
|
|
$ |
3,503 |
|
| Lymphoseek license revenue |
|
|
83 |
|
|
|
250 |
|
|
|
550 |
|
|
|
250 |
|
| Grant and other revenue |
|
|
190 |
|
|
|
654 |
|
|
|
477 |
|
|
|
541 |
|
| Gross profit |
|
|
1,659 |
|
|
|
2,535 |
|
|
|
3,522 |
|
|
|
3,778 |
|
| Operating expenses |
|
|
9,475 |
|
|
|
6,346 |
|
|
|
7,845 |
|
|
|
6,379 |
|
| Operating loss |
|
|
(7,816 |
) |
|
|
(3,811 |
) |
|
|
(4,323 |
) |
|
|
(2,601 |
) |
| Net loss attributable to common stockholders |
|
|
(7,337 |
) |
|
|
(9,691 |
) |
|
|
(8,071 |
) |
|
|
(2,510 |
) |
| Basic and diluted net loss per share (1) |
|
$ |
(0.05 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.05 |
) |
|
$ |
(0.02 |
) |
| (1) |
Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation. |
|